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INTRODUCTION 
Infective endocarditis caused by viridans streptococci, 
enterococci or other streptococci accounts for at least 
55-65% of all cases of native valve endocarditis in non- 
addicts. The recommendations are a consensus of the 
Endocarditis Working Group that analyzed the results 
of clinical trials in humans and studies of experimental 
endocarditis in animals. The group recognizes that 
these data are incomplete or inconclusive in some 
groups of patients. The recommendations presented in 
this report for the use of ceftriaxone, gentamicin, 
netilmicin or teicoplanin are based upon the results of 
relatively small clinical trials in humans or animal model 
studies of experimental endocarditis. Additionally, 
there are minimal clinical data published regarding the 
optimum regimens for the treatment of penicillin-, 
vuncomycin- or aminoglycoside-resistant enterococcal 
endocarditis. The recommendations for treatment 
of patients with endocarditis caused by Streptococctrs 
przeumoniae, S. pyogenes or group B, C or G streptococci 
are based on reports of treatment of a small number of 
patients, individual case reports, or results of experi- 
mental endocarditis treatment regimens. None the 
less, this report represents what the Subcommittee on 
Endocarditis believes to be reasonable and prudent 
recommendations for antimicrobial therapy of these 
patients. 
GENERAL GUIDELINES FOR TREATMENT OF 
STREPTOCOCCAL ENDOCARDITIS 
Table 1 presents general guidelines for the use of 
antimicrobial therapy in patients with streptococcal 
endocarditis. The dosages recommended are intended 
as initial therapy for adults with normal renal and 
hepatic function. After initiation of antimicrobial 
therapy, serum concentrations of aminoglycosides, 
vancomycin or teicoplanin should be monitored 
carefully and dosages adjusted to achieve concentrations 
in serum approximating to those outlined in Table 2. 
The committee recognizes that for the treatment of 
patients with viridans streptococcal endocarditis with 
aminoglycoside-containing regimens, some clinicians 
prefer to administer gentamicin, netilmicin or tobra- 
mycin dosages twice daily or in a single daily dose. 
Animal model studies and two recent clinical trials 
suggest that ceftriaxone or penicillin combined with a 
single daily dose of netilmicin or gentamicin are 
effective therapy [ 1-71, 
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Table 1 General guidelines for antimicrobial therapy for patlents with streptococcal or enterococcal endocarditis 
Dosages for antibiotics are as shown in Tables 2-4. The dosages recommended for aminoglycosides and vancomycin are suggested initial 
d o y a p .  The  dosage of teicoplanin should be 10 mg/kg every 12 h for nine doses, then 10 mg/kg per day thereafter. Most of the publishcd 
data for aiiiinoglycoside use are with strepton~vcin or gentamicin, and for glycopeptides with vancomycin. Recommendations for use of  
iirtilmicin, tobramycin or teicoplanin are based on results of relatively small clinical trials in humans or animal model studies of experimental 
endocarditis. Based on thew studies, dosages of antimicrobials should be adjusted to result in approximate serum concentrations as follows: 
mg/L of Serum 
l h  Trough 
<;cntamicin, tohraniyciri, nrtilrnicin 53.0 <1 
Strcptoniycin 20-40 55.0 
Vancomycin 30-15 515 
Teicoplanin 30-40 112 
I n  patients Lvith viridans streptococcal or S. bows endocarditis caused by a penicillin susceptible strain (MIC 10.1 ing/L), relative 
coiitraindications for the use of gentamicin, tobramycin or netilnllcin are renal or VIII cranial neme impairment. 
Strains of enterococci should be screened for antibiotic resistance in vitro as follows: 
Aii t ibiot~ Resistance breakpoint (MIC, mg/L) 
~~ 
l’enicillin 
Am piciuin 
Gentaniicin 
Vancomycin oi- teic~oplaniii 
s tr ‘p tolllycl I1 
28 
28 
>SO0 
>2000 
<4 susceptible; 8-16 intermediate; 232 reslstant 
VlRlDANS STREPTOCOCCI AND S. BOVlS 
The viridans group of streptococci produce a- 
heniolysiy on blood agar plates and comprise a 
heterogeneous group of microorganisms that includes 
S. sanguis, S. salivatius, S. mutans, and others. Viridans 
streptococci are the most common microbiological 
cause of infective endocarditis in non-addicts and 
viridans streptococci and S.  bouis account for 45-500/1 
of cases involving native valves 181. Despite highly 
effective antimicrobial regimens for the treatment of 
patients with viridans streptococcal endocarditis, the 
mortality rate remains approximately 10% (8). 
Highly penicillin-susceptible viridans streptococcal or 
S. bovisendocarditis (MIC 50.1 mg penicillin per 1) 
The suggested regimens for antimicrobial therapy of 
endocarditis due to viridans streptococci or S. bouis 
susceptible to penicillin (MIC 50.1 mg/L) are shown 
in Table 2A. Among patients who survive to complete 
therapy with regimens 1, 2 or 3 in Table 2A, the 
bacteriologic cure rate i s  approximately 98% [ 8 ] .  
Aqueous penicillin G or ceftriaxone appear to be 
equally effective as monotherapy. The major advantage 
of ceftriaxone therapy over aqueous penicillin G or 
other cephalosporins is that it  may be administered as a 
single daily dose intravenously or intramuscularly, 
which significantly facilitates outpatient therapy. This is 
extensively discussed in the current issue (1’. Francioli 
and D. Stamboulian). Francioli et a1 [9] reported a 100% 
cure rate among 55 patients with viridans streptococcal 
endocarditis treated for 4 weeks with ceftriaxone. Prior 
to this report, the majority of studies were reported on 
hospitalized patients. The study by Francioli et al. is 
important for several reasons. First, this report confirms 
and extends a previous study by Stamboulian et a1 [ 101, 
which demonstrated that 4 weeks of ceftriaxone 
therapy was effective for penicillin-susceptible ytrepto- 
coccal endocarditis. Second, the study by Francioli 
et a1 demonstrated that outpatient therapy with 
ceftriaxone is feasible and well tolerated for selected 
patients with endocarditis. In this study, 39% of patients 
were discharged from hospital within 2 weeks of the 
onset of therapy; 15% were hospitalized for 7 days or 
less. Third, the study emphasized an important 
advantagc of ceftriaxone therapy in that it may be 
administered either intramuscularly or intravenously. 
Twelve per cent of patients in this study received 
ceftriaxone administered intramuscularly either in part 
or in total. The intramuscular administration of 
ceftriaxone further facilitates outpatient therapy of 
patients with streptococcal endocarditis. 
Francioli et al. carefully selected patients for out- 
patient therapy. Patient compliance and the possible 
occurrence of heart failure, peripheral embolization, or 
other complications of endocarditis that could develop 
during outpatient therapy Are major reasons why other 
investigators have been reluctant to utilize outpatient 
therapy. While heart failure may develop during 
antimicrobial therapy, the majority of patients with heart 
failure have some degree of heart failure on admission 
to hospital [I 1). Patients with heart failure coniplicating 
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Table 2 Suggested regimens for treatment of endocarditis due to viridans streptococci or S. bovir 
Duration (weeks) Antibiotic Dosage 
A. Penicillin susceptibility 40.1 mg/L 
Aqueous penicillin G 
ceftriaxone 
Aqueous penichn G 
gentamicin or 
tobramycin 
Ceftriaxone 
or 
plus 
plus 
netilmicin or 
gentamicin 
Vanrornycin 
or 
12-24 million units/24 h 1V connnuously 01 
2 g IV or IM q24h single dose 
Dosage as above 
in equally divided doses 
1 mg/kg IV or IM q8h 
Dosage as above 
4 mg/kg IV q24h daily single dose 
3 mg/kg IV or IM q24h single daily dose 
30 mg/kg/day IV in 2 dwided doses 
teicoplanin 10 mg/kg IV or IM q12h for 9 doses then 
10 mg/kg/day thereafter 4 
1. Aqueous penicfin G Dosage as above 4 
gentamicin’ or Dosage as above 2 
tobramycin‘ or 2 
netilmicin‘ 2 
B. Peniciuin susceptibility >0.1 mg/L to 50.5 mg’L or prosthetic valve endocarditis with MIC 50.1 mg/L” 
or ceftriaxone 4 
plus 
2. Vancomycin or 
teicoplanin 
Dosage above 4-6 
4-6 
C. Penicillin MIC >0.5 rng/L or Abiotrophia sp (nutritionally variant viridans streptococci) or prosthenc valve endocarditis with MIC 
>0.1 mg/L 
1. Aqueous peniciUin G Dosage as above 4-6 
or ceftriaxone 4-f ,  
plus 
gentamicinb or Dosage as above 46 
tobramycinb or 4-6 
netilmicin’ 4-6 
2. Vancomycin or Dosage as above 4-6 
teicoplanin 4-6 
a Prosthetic valve endocarditis-duration of p-lactarn therapy should be 4-6 weeks, together with aminoglycoside therapy for the first 2 
weeks of therapy. Vancomycin or teicoplanin therapy should be administered for 4-6 weeks. There are insufficient data to recommend the 
addition of an aminoglycoside to vancomycin or teicoplanin therapy. 
‘ Only limited experience with aminoglycosides administered in one daily dose. 
endocarditis should not be treated as outpatients and 
should be readmitted to hospital promptly if heart failure 
develops during outpatient therapy. Outpatients should 
have prompt access to facilities where surgical inter- 
vention can be performed if necessary. 
Among patients with streptococcal endocarditis, 
peripheral embolic events usually occur either prior to 
admission to hospital or early during the period of 
antimicrobial therapy. The rate of embolic events 
declines sharply after the onset of effective anti- 
microbial therapy 1121. Bacterial vegetations may be 
visualized by transthoracic echocardiography (TTE) or 
transesophageal (TEE) echocardiography. The sensi- 
tivity for vegetations of TTE is less than 60% compared 
with a sensitivity of 76-100% for TEE [13-191. 
Exclusion of these patients from consideration for 
outpatient therapy solely on this basis would severely 
limit the number of patients eligible for outpatient 
treatment. Patients with streptococcal endocarditis who 
have experienced embolic events should not be treated 
as outpatients. Until more data are available, the 
committee would not disqualifj. patients from out- 
patient therapy based solely on the presence of cardiac 
valvular vegetations detected by echocardiography. The 
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risk of embolization is highest among patients with 
vegetations larger than 1 cm which are located on the 
anterior leaflet of the mitral valve and among patients 
with vegetations on either the mitral or aortic valve 
that increase in size during therapy [20,21]. It seems 
prudent to exclude these subsets of patients from 
outpatient therapy. Outpatients who experience an 
embolic event during therapy should be hospitalized 
and observed closely during the remainder of anti- 
microbial therapy so that prompt surgical intervention 
may be performed if necessary. 
The addition of an aminoglycoside (streptomycin, 
gentainicin, netilmicin, or tobramycin) to penicillin 
therapy exerts a synergistic killing effect on viridans 
streptococci in vitro and in vivo [l]. The cure rate 
following completion of a course of combined therapy 
is approximately the same as that resulting from 4 weeks 
of monotherapy with penicillin or ceftriaxone for 
penicillin-susceptible streptococcal endocarditis [8 ] .  
Several large series have been reported which have used 
a combination of penicillin and an aminoglycoside for 
treatment of viridans streptococcal endocarditis 
[11,22-241. Although older studies reported a failure 
rate of 6-1 1% with the 2-week regimen, more recent 
studies have reported bacteriologic cure rates of at  least 
98%) in patients who completed a 2-week course 
[8,22-263. The results of a multicenter study in Europe 
and South America suggest that 2 weeks of therapy 
with the combination of ceftriaxone and netilmicin 
administered 111 single daily doses is equivalent to 2 
weeks of treatment with penicillin and streptomycin or 
gentamicin 131. Additionally, a recent multicenter study 
comparing 4 weeks of ceftriaxone administered in a 
single daily dose with 2 weeks of treatment with cefiri- 
axone combined with gentamicin, each administered in 
a single daily dose, demonstrated that these two regi- 
mens are equally effective [4]. The 2-week regimens are 
appropriate for uncomplicated penicillin-susceptible 
viridans streptococcal or S. bovic endocarditis in patients 
who are at low risk for aminoglycoside-associated 
toxicity. The 2-week regimens are not recommended 
for patients with extracardiac foci of infection or 
intracardiac abscess. 
Although most reported clinical experience with 
penicillin-aminoglycoside therapy involves the use of 
penicillin and streptomycin, in vitro animal model 
studies and limited clinical data suggest that the 
combination of penicillin together with either genta- 
micin, netilmicin or tobraniycin is at  least as effective 
as therapy with penicillin and streptomycin [1,2,27]. 
Gentamicin, netilmicin and tobraniycin are more 
widely used in clinical practice than is streptomycin, 
and determinations of gentamicin, netilmicin or 
tobramycin concentrations in serum are more easily 
done. Moreover, gentamicin, netilmicin or tobramycin 
may be administered either intravenously or intra- 
muscularly. Accordingly, the group believes that 
gentamicin, netilmicin or tobramycin should be 
considered interchangeable and preferable to strepto- 
mycin in combination with penicillm for the treatment 
of penicillin-susceptible viridans streptocccal or S. bavis 
endocarditis. 
For patients unable to tolerate penicillin or 
cephalosporins, vanconiycin or teicoplanin are alter- 
native drugs (Table 2A). Early reports suggesting an 
unacceptably high failure rate in patients with endo- 
carditis were associated with teicoplanin regimens 
utilizing relatively low dosages of teicoplanin [28]. 
Viridans streptococcal (penicillin susceptibility 
>0.1 mg/L to $0.5 mg/L) or prosthetic valve endocarditis 
(penicillin susceptibility 50.1 mg/L) 
Table 2B outlines the recommended regimens for 
patients with endocarditis caused by relatively 
penicillin-resistant strains or for patients with prosthetic 
valve endocarditis caused by highly penicillin- 
susceptible strains. Based on limited published data, the 
subcommittee reconimends that aqueous penicillin G 
or ceftriaxone be administered for 4 weeks together 
with either gentamicin, netilmicin, or tobramycin for 
the first 2 weeks of therapy. For patients unable to 
tolerate P-lactam therapy, the subcommittee suggests 
the use of vancomycin or teicoplanin for 4-6 weeks. 
There are currently insufficient published data to allow 
the recommendation of the addition of an amino- 
glycoside to vanconiycin or teicoplanin therapy for 
these patients. 
For patients with prosthetic valve endocarditis 
caused by highly penicillin-susceptible strains, the 
duration of p-lactam therapy should be 4-6 weeks, 
with an aminoglycoside being administered for the first 
2 weeks of treatment. Vancomycin or teicoplanin 
should be administered for at  least 4 but preferably 6 
weeks. As with native valve endocarditis, there are 
insufficient published data to justify the recomniend- 
ations of the addition of a n  aminoglycoside to 
vancoriiyciii or teicoplanin therapy for prosthetic valve 
endocarditis. 
Viridans streptococcal (penicillin MIC >0.5 mg/L) or 
nutritionally variant viridans streptococcal endocarditis 
or prosthetic valve endocarditis with strains caused 
by penicillin MIC >0.1 mgfL) 
Among patient$ who are not allergic to penicillin, the 
subcomrmttee reconimends therapy similar to that for 
patients with enterococcal endocardltis [8] The therapy 
of choice for these patients should be aqueous penicillin 
G or ceftriaxone together with an aminoglycoside 
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administered for 4-6 weeks (Table 2C). In patients 
unable to tolerate penicillin, the group suggests the 
use of monotherapy, either vancomycin or teicoplanin, 
administered for a minimum of 6 weeks. There are 
currently insufficient published data to recommend the 
addition of an aminoglycoside in patients treated with 
either vancomycin or teicoplanin, and the benefit of 
potential synergistic activity should be balanced against 
the fact that vancomycin may enhance the nephro- 
toxicity or ototoxicity of aminoglycosides. 
ENTEROCOCCAL ENDOCARDITIS 
Enterococci account for 10-15% of cases ofnative valve 
endocarditis in nonaddicts [8,29]. Currently, there are 
at  least 12 species within the genus Enterococcus; E. 
faecalis and E. faecium are the most common species 
recovered from patients with endocarditis. The 
treatment of patients with enterococcal endocarditis is 
complicated by the fact that these organisms are 
relatively resistant in vitro to penicillin (median MIC 
2 mg/L), vancomycin and teicoplanin. Enterococci are 
inhibited but not killed by these drugs alone; these 
microorganisms are uniformly resistant to cephalo- 
sporins. The combination of penicillin, ampicillin, 
vancomycin or teicoplanin with either streptomycin or 
gentamicin acts synergistically in vitro or in vivo to kill 
susceptible strains of enterococci. 
During the last two decades, enterococci have 
developed increasing resistance to aminoglycosides, 
penicillins, and vancomycin. MICs of 22000 mg/L 
streptomycin and 500-2000 mg/L of gentamicin are 
considered the breakpoints between susceptible and 
resistant strains of enterococci. The most common 
mechanism of aminoglycoside resistance of enterococci 
is the result of plasmid-mediated enzymes which 
inactivate streptomycin or gentamicin [30]. Less 
commonly, enterococci may be resistant as a result of 
decreased uptake of aminoglycosides through the cell 
wall or decreased binding of aminoglycosides to 
ribosomes [30]. High-level resistance of enterococci 
to gentamicin is related to the production of the 
bifunctional enzymes phosphotransferase and acety- 
transferase, which inactivate all clinically available 
anlinoglycosides except Streptomycin. Enterococci that 
exhibit high-level resistance to streptoinycin as a result 
of the production of an adenylating enzyme may 
remain susceptible to gentamicin. Enterococci that are 
highly resistant to gentamicin or streptomycin are not 
killed synergistically in vitro or in vivo by a 
combination of penicillin, vancomycin or teicoplanin 
with the aminoglycoside. Patients with amino- 
glycoside-susceptible enterococcal endocarditis may be 
treated successfully with a regimen containing either 
streptomycin or gentamicin. Gentamicin is considered 
to be the aminoglycoside of choice for treatment of 
these patients, because gentamicin is more readily 
available than streptomycin, serum concentrations of 
gentamicin are more easily attainable than those of 
streptomycin, and gentamicin-associated toxicity is 
more often reversible than that associated with 
streptomycin. The increasing prevalence of high-level 
resistance to gentamicin and streptomycin among 
enterococci requires that susceptibility tests to both 
streptomycin and gentamicin be evaluated carefully. 
Aminoglycosides other than gentamicin or strepto- 
mycin cannot routinely be substituted for either 
streptomycin or gentamicin, and nor do the MICs of 
other aminoglycosides against enterococci reliably 
predict in vitro bactericidal synergy. 
In addition to high-level resistance to amino- 
glycosides, a substantial proportion of enterococcal 
isolates are increasingly resistant to penicillin, ampicillin 
and vancomycin. Intrinsic resistance to penicillin and 
ampicillin with MICs 232 mg/L has been recognized 
in enterococci, particularly with E. faecium [3 I]. 
Moreover, 0-lactamase-producing strains of E.  faecalis 
have been recovered [32]. This form of resistance to 
penicillin or ampicillin will not be detected by routine 
MIC testing with standard inocula of enterococci. 
Strains of enterococci recovered from patients with 
endocarditis should be screened for p-lactamase pro- 
duction using the chromogenic cephalosporin, nitro- 
cephin. 
Resistance to vancomycin has been recognized 
with increased frequency in strains of E. faecalis and 
E. faecitim [33]. Some strains of vancomycin-resistant 
enterococci exhibit relatively low to intermediate levels 
of vancomycin resistance (MIC 8-16 mg/L). These 
strains usually remain susceptible to teicoplanin (van B). 
Other strains of VRE are highly resistant to both 
vancomycin and teicoplanin (MIC >32 mg/L) (van A). 
High-level resistance in these VRE is plasmid medi- 
ated, transferable, and inducible. Strains of VRE which 
are resistant to vancomycin or teicoplanin are not killed 
synergistically by the respective drug in Combination 
with an aminoglycoside. Because of the potential for 
enterococci to be resistant to one or more amino- 
glycosides, penicillin, ampicillin, vancomycin, and 
teicoplanin, strains of enterococci recovered from 
patients with endocarditis should be screened for 
resistance patterns to these antimicrobials as outlined in 
Table 1. 
Penicillin-, aminoglycoside-, and vancomycin-susceptible 
enterococcal endocarditis 
The overall cure rate for patients with endocarditis 
caused by these strains of enterococci is approximately 
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Table 3 Suggested regimens for treatment of enterococcal endocarditis 
Dosage Duration (weeks)’ Antibiotic 
A. Penicillin-, anlinoglycoside and vancomycin-susceptible strains 
1. Aqueous penicillin G 12-24 mllion units/24 h IV continuously or in 4-6 
ampicillin or amoxycillin 175 mg/kg/day IV in divided doses 1 4  
or divided doses 
plus 
gentamicin 1 nig/kg IV or IM q8h 4-6 
2. Vancomycin 30 mg/kg/day in 2 divided doses 4-6 
gentamicin Dosage as above C 6  
plus 
B. Penicillin-, vancomycin- and streptomycin-susceptible, gentamicin-resistant strains 
Penicillin, ampicillin, 
vanconiycin 
amoxycillin, or Dosage as above 1 4  
plus 
streptomycin 7.5 mg/kg IM q12h 1-6 
C .  Penicillin-allergic patient with vancomycin-resistant, teicoplanin-susceptible and gentamicin-susceptible strains 
1. Teicoplanin 10 mg/kg IV or IM q12h for 9 doses, C h  
plus then 10 mg/kg/day IV or IM thereafter 
gentamicin Dosage as above 4-6 
11. Penicillin-resistant (MIC >8 mg/L), vancomycin-susceptibleb and anlinoglycoside-susceptible ?train? 
1. Intrinsic penicillin resistance 4-6 
Vancomycin Dosage as above 
plus 
gentairiicin 
2. P-Lactamase mediated 
a. Ampicillin/amoxycillin- 
Dosage as above 1-6 
175 mg/kg/day of ampicillin or amoxycillin in 4-6 
~ulbactani/clavulanic acid divided dose? 
gentamiciii Dosage as above 
plus 
4-6 
b. Vancomycin 
plus 
Dosage as above 
gentaiiiicin Dosage as above 4-6 
E. Multiply ammoglycoside-resistant strains 
1. Ampicillin or amoxycilhn >200 mg/kg/day in divided doses or by continuous 
infusion 
2. Perform killing curves with multiple - 
drug regimens and use most 
effective combination of agents 
(see text) 
3.  Cardiac valve replacement 
plus antibiotics as above 
28 
28 
a Four weeks of therapy are recommended for patients with symptoms less than 3 months in duration; 6 weeks of therapy are recommended 
for patients with symptoms longer than 3 months in duration. There are insufficient data to allow the recommendation of either a 4- or 
6- week duration of therapy for vancomycin- or teicoplanin-containing regimens. Therapy with these drugs should be a minimum of 4 
weeks in duration and most authorities recommend 6 weeks of therapy. The duration of therapy for prosthetic valve endocarditis should be 
6 weeks. 
Teicoplanin should be SubShtUted for vancomyciii therapy in patients with endocarditis caused by a vancomycin-resistant main. 
75%, which is lower than that for endocarditis due to streptomycin, gentamicin and vancomycin are outlined 
viridans streptococci or S. bovir [8,34]. The anti- in Table 3A. The regimen of choice for these patients 
microbial regimens considered appropriate for the is considered to be aqueous penicillin G, ampicillin or 
treatment of patients with endocarditis caused by strains amoxycillin together with gentamicin administered for 
of enterococci which are susceptible to penicillin, 4-6 weeks. The dose of gentamicin should be 
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adrmnistered every 8 h. Most, but not all, animal model 
studies of experimental enterococcal endocarditis 
suggest that single daily dosing with an aminoglycoside 
is less effective than divided daily doses [35-381. 
Following initiation of gentamicin therapy, the dosage 
of gentamicin should be adjusted to achieve a 1-h 
concentration in serum of approximately 3 mg/L and 
a trough of <1 mg [8,34]. Therapy should continue for 
a minimum of 4 weeks. Patients with symptoms of 
infection less than 3 months in duration before insti- 
tution of appropriate antimicrobial therapy may be 
treated successfully for 4 weeks; patients with symp- 
toms of infection longer than 3 months in duration or 
patients with prosthetic valve endocarditis should receive 
6 weeks of combined antimicrobial therapy [8,34]. 
In patients who are penicillin allergic, the group 
recommends therapy with vancomycin together with 
gentamicin. The serum concentration of vancomycin 
should be adjusted according to Table 1. Currently, 
there are insuflicient data to allow the recommendation 
of either a 4- or 6-week duration for vancomycin- 
gentamicin therapy. However, many authorities believe 
that vancomycin is less effective than p-lactam therapy 
of enterococcal endocarditis and that the combination 
of vancomycin and gentamicin should be administered 
for a total of 6 weeks rather than 4 weeks. 
Penicillin-, vancomycin-, and streptomycin-susceptible, 
gentamicin-resistant enterococcal endocarditis 
For patients with endocarditis caused by a gentamicin- 
resistant, streptomycin-susceptible strain of enterococci, 
streptomycin therapy is recommended (Table 3B). 
Streptomycin should preferably be administered intra- 
muscularly. Limited data suggest that streptomycin may 
also be safely administered intravenously [8].  After 
initiation of streptomycin therapy, concentrations in 
serum should be monitored and adjusted to achieve a 
1-h concentration of approximately 20-40 mg/L and a 
trough of 110 mg/L [34]. Streptomycin is primarily 
ototoxic, while gentamicin is primarily nephrotoxic; 
while gentamicin-associated nephrotoxicity is revers- 
ible, streptomycin-associated ototoxicity is not. The 
duration of therapy should be either 4 or 6 weeks, 
depending upon the duration of symptoms prior to the 
initiation of antimicrobial therapy as outlined above. 
For patients unable to tolerate penicillin or ampicillin, 
the committee suggests the combination ofvancomycin 
and streptomycin as discussed above. 
Penicillin-allergic patient with vancomycin-resistant, 
teicoplanin- and gentamicin-susceptible enterococcal 
endocarditis 
Table 3C outlines the group recommendation for 
treatment of patients with endocarditis caused by these 
strains. The group suggests that the dosage of 
teicoplanin should be 10 mg/kg twice daily for nine 
doses and then 10 mg/kg daily thereafter, and should 
be administered together with gentamicin for at least 4 
but preferably 6 weeks. The concentrations in serum of 
gentamicin, vancomycin, and teicoplanin should be 
adjusted as outlined in Table 1. Breakpoints for 
vancomycin and teicoplanin resistance are shown in 
Table 1. Strains which are susceptible to both 
teicoplanin and vancomycin (MIC 14 mg/L) should be 
treated preferentially with vancomycin. Intermediate 
vancomycin-resistant strains (MIC 4-16 mg/L, van B) 
usually remain susceptible to teicoplanin [30]. Patients 
with infection caused by these organisms should 
be treated with teicoplanin in combination with 
gentamicin or streptomycin. Strains with high-level 
vancomycin or teicoplanin resistance have MICs 
232 mg/L. The combination of vancomycin or teico- 
planin and an aminoglycoside does not synergistically 
kill these strains of enterococci. In these patients, 
treatment should be individualized as for cases with 
multiply aminoglycoside-resistant strains (see below). 
Penicillin-resistant, vancomycin- and aminoglycoside- 
susceptible enterococcal endocarditis 
Resistance of enterococci to penicillin or ampicillin 
may be either intrinsic or p-lactamase mediated, as 
described above. Table 3D outlines the group 
recommendations for the treatment of patients with 
enterococcal endocarditis caused by these strains. 
Intrinsic resistance to penicillin is more common than 
P-lactamase-mediated resistance. For endocarditis caused 
by enterococci intrinsically resistant to penicillin, the 
group suggests the combination of vancomycin and 
gentamicin in the dosages outlined in Table 3A for 
a minimum of 4 weeks. For strains of enterococci 
that produce P-lactamase, the group suggests therapy 
with ampicillin/arnoxycdlin-sulbactam/clavulanic acid 
together with gentamicin. In patients unable to tolerate 
penicillin, the committee recommends the combin- 
ation of vancomycin and gentamicin as outlined in 
Table 3A. Teicoplanin may be substituted for vanco- 
mycin in patients with endocarditis caused by a 
vancomycin-resistant strain of enterococci. 
Multiply aminoglycoside-resistant strains 
In patients with infection caused by an enterococcal 
strain that exhibits high-level resistance to gentamicin 
and streptomycin, the combination of an amino- 
glycoside together with either penicillin, vancomycin 
or teicoplanin will not synergistically kill these strains. 
In these patients, prolonged therapy (8 weeks) with 
high dosages of ampicillin or amoxycillin is recom- 
mended (Table 3E). Alternatively, the group suggests 
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that killing curves with multiple-drug regimens in- 
cluding ampicillin, vancomycin, teicoplanin, imipenem, 
fluoroquinolones and other agents may be performed 
[38-431. Therapy should be instituted with the most 
effective combination of agents for at least 8 weeks. As 
for cases infected with glycopeptide-resistant strains, 
the group suggests that these patients be treated in 
consultation with an infectious diseases specialist. 
Combinations of drugs and new compounds are under 
investigation and have shown some encouraging results 
[38-431. Antimicrobial therapy alone may not result in 
cure, and those patients failing therapy should be 
considered as candidates for cardiac valve replacement 
surgery. 
S. PNEUMONIAE, S. PYOGENES, AND 
GROUP B, C AHD G STREPTOCOCCI 
Endocarditis caused by these microorganisms is rela- 
tively uncommon. There are no published reports of 
large series of cases comparing therapeutic regimens for 
these patients. The recommendations for antimicrobial 
therapy outlined in Table 4 are based on limited clinical 
data in humans and animal studies of experimental 
endocarditis. Despite the relative lack of data, the 
group believes that these recommendations are 
reasonable and prudent. For endocarditis caused by 
penicillin-susceptible S. pneumoniae or S. pyogenes, the 
committee recommends 4-6 weeks of therapy with 
aqueous penicillin G or ceftriaxone. While there are 
no published data on the use of ceftriaxone in these 
patients, experience with this drug in the treatment of 
patients with viridans streptococcal endocarditis suggests 
that ceftriaxone should be effective therapy for endo- 
carditis caused by these streptococci. S. pneumoniae 
recovered from patients with endocarditis should be 
screened for penicillin resistance (MIC 21 mg/L). 
Identification of appropriate antimicrobial therapy 
depends upon the results of susceptibility tests with 
cephalosporins, vancomycin, and other antimicrobial 
agents. Treatment of patients with endocarditis caused 
by multiply-resistant strains of S. pneurnorziae should be 
performed in consultation with an infectious diseases 
specialist. Strains of group B, C or G streptococci are 
slightly more resistant in vitro to penicillin than are 
group A streptococci (S. pyo'qeues). Treatment of 
endocarditis caused by these organisms should be for 
4-6 weeks with aqueous penicihn G, a first-generation 
cephalosporin, or ceftriaxone. The combination of a p- 
lactam together with an aminoglycoside usually acts 
synergistically in vitro and in experimental infections 
against group B, C or G streptococci [44]. Based on 
these data, some authorities recommend the addition 
of an aminoglycoside to penicillin or cephalosporin 
therapy for at  least the first 2 weeks of a 4-6 week 
course of antimicrobial therapy [45]. 
Penicillin-allergic patients should be treated with 
vancomycin. Although there are virtually no published 
data on the use of teicoplanin in these patients, 
teicoplanin therapy should presumably be an effective 
alternative to vancomycin provided that the dosage of 
teicoplanin is as outlined in Table 2. 
Table 4 Suggested regimens for treatment of endocarditis caused by S. pnetrmoniae, S. pyogenes, or streptococcus group B, C, 
o r  G" 
Antibiotic Dosage Duration (weeks) 
A. S. pneumoniae (penicillin susceptible)b or S. pyogenes 
1. Aqueous penicillin G 12-24 million units/24 h IV continuously 1-6 
or or in divided doses 
ceftriaxone 2 g 1V/24 h IV or IM single dose 4-6 
2. Vancomycin 30 mg/kg/day IV in 2 divided doses 4-6 
B. Group B, C or G streptococci 
1 .  Aqueous penicillin G or Dosagr as above 
ccfiriaxonc' 
4-6 
2. Vanconiycin Dosage as above 4-6 
~' Treatment regimens are based upon results of therapy in a number of  small clinical studies or upon results of  studies of experimental 
endocarditis 
'' S. pneumoniae with MIC of penicillin >1 mg/L. The committee recommends wsceptibihty tests to ceftriaxone (or other cephalosporins), 
imipenem, meropenem, and vancomycin; the most active agent in vitro should be administered for 4-6 wccks 
Some authorities suggest that an aminoglycoside (gentamicin or netilnlicin) be added to penicillin or ceftriaxone therapy for the first 2 
weeks of treatment 
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MONITORING THE EFFICACY OF ANTIMICROBIAL 
THERAPY 
The most important aspect of the monitoring ofpatients 
being treated for endocarditis is careful clinical 
examination. The persistence or recurrence of fever in 
patients receiving appropriate antimicrobial therapy for 
endocarditis may be due to many causes other than 
treatment failure, including drug fever, thrombo- 
phlebitis, or embolization. In patients with penicillin- 
susceptible viridans streptocccal or S. bovis endocarditis, 
persistence or recurrence of fever as a result of treatment 
failure is rare, especially in those patients whose fever 
recurs after an initial defervescence. Drug fever is a 
common cause of recurrence of fever in these patients. 
In patients who fail to defervesce, appropriate investig- 
ations should be made, including TEE. Patients with 
enterococcal endocarditis caused by a strain resistant to 
multiple antibiotics may have persistence of fever despite 
administration of single- or multiple-drug therapy. 
In the past, the serum bactericidal titer (SBT) was 
widely used to assess the efficacy in vivo of antimicrobial 
therapy in patients with endocarditis. The results of 
these tests vary among laboratories and according to 
methods used, and SBT testing has not been validated 
fully under clinical circumstances. Accordingly, the 
group does not recommend routine use of the SBT for 
assessing the efficacy of antimicrobial therapy. The SBT 
may be useful in patients where a response to therapy is 
suboptimal, when endocarditis is due to an unusual 
organism or is caused by a multiply-resistant strain, or 
in patients receiving unconventional treatment regimens. 
Most authorities agree that a peak SBT of 1:8 or greater 
is desirable. 
Patients with endocarditis should be followed 
carefully after completion of therapy. It is generally 
recommended to obtain blood cultures once or twice 
during the 8 weeks following completion of antibiotic 
treatment, especially in patients with prolonged or 
recurrent febrile states. Among patients with strepto- 
coccal endocarditis, the large majority of relapses 
usually occur within 4 weeks after completion of 
antimicrobial therapy, and blood cultures should be 
obtained promptly in case of symptoms or signs 
suggesting relapse. 
The most common cause of death among patients 
with endocarditis is congestive heart failure resulting 
from valvular dysfunction. Urgent surgical intervention 
may be necessary in patients with severe or sudden 
onset of heart failure. Patients who have heart failure at 
the time of admission to hospital for treatment of 
endocarditis, or those who develop heart failure during 
therapy, should be followed closely after completion of 
antimicrobial therapy for worsening of heart failure. 
These patients should have access to facilities where 
prompt surgical intervention can be accomplished if 
necessary. Surgery should also be considered for 
patients with resistant enterococcal endocarditis and for 
patients with relapsing prosthetic valve endocarditis. 
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